Amgen Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 At ASCO 2019
AMG 510 is the First KRASG12C Inhibitor to Reach Clinical Stage After Three Decades of RAS Research
First-In-Human Results Show Preliminary Safety, Tolerability Data and Anti-Tumor Activity in KRAS Mutant Solid Tumors
FDA Grants AMG 510 Orphan Drug Designation for KRASG12C-Positive Non-Small Cell Lung and Colorectal Cancers
THOUSAND OAKS, Calif., June 3, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the first clinical results from a Phase 1 study evaluating investigational AMG 510, the first KRASG12C inhibitor to reach the clinical stage. In the trial, there were no dose-limiting toxicities at tested dose levels. AMG 510 showed anti-tumor activity when administered as a mono...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Grants | Non-Small Cell Lung Cancer | Pharmaceuticals | Study | Toxicology